Allianz Asset Management GmbH Invests $476,000 in Cellebrite DI Ltd. (NASDAQ:CLBT)

Key Points

• Allianz Asset Management GmbH has invested $476,000 in Cellebrite DI Ltd., acquiring 24,505 shares during the first quarter.
• Cellebrite DI recently reported $0.10 earnings per share, beating estimates, with revenue increasing by 20% year-over-year.
• Analysts have mixed ratings on Cellebrite DI, with a consensus rating of "Moderate Buy" and an average target price of $22.43.

Allianz Asset Management GmbH acquired a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 24,505 shares of the company's stock, valued at approximately $476,000.

Several other large investors also recently made changes to their positions in the stock. Jennison Associates LLC bought a new stake in shares of Cellebrite DI during the first quarter worth $645,000. Sigma Planning Corp acquired a new stake in shares of Cellebrite DI in the first quarter valued at approximately $233,000. Envestnet Asset Management Inc. acquired a new stake in shares of Cellebrite DI in the first quarter valued at approximately $512,000. Bank of New York Mellon Corp acquired a new stake in shares of Cellebrite DI in the first quarter valued at approximately $22,428,000. Finally, Catalyst Capital Advisors LLC acquired a new stake in shares of Cellebrite DI in the first quarter valued at approximately $51,000. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Trading Down 2.0%

NASDAQ:CLBT opened at $13.70 on Friday. Cellebrite DI Ltd. has a 1-year low of $11.90 and a 1-year high of $26.30. The firm has a fifty day simple moving average of $15.52 and a 200 day simple moving average of $18.42. The stock has a market capitalization of $3.28 billion, a PE ratio of -14.27, a P/E/G ratio of 2.76 and a beta of 1.27.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.01. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. The business had revenue of $107.55 million during the quarter, compared to analysts' expectations of $109.36 million. During the same period last year, the business earned $0.08 earnings per share. The firm's revenue was up 20.0% on a year-over-year basis. On average, equities analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Cellebrite DI from a "buy" rating to a "hold" rating in a report on Saturday. Needham & Company LLC reiterated a "buy" rating and issued a $24.00 price objective on shares of Cellebrite DI in a report on Friday, June 6th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday, May 12th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Cellebrite DI currently has a consensus rating of "Moderate Buy" and an average target price of $22.43.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.